Osimertinib as Salvage Therapy in Advanced Non‐Small Cell Lung Cancer After Aumolertinib Resistance With T790M Mutation: A Case Report

ABSTRACT The third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is recommended universally as the standard treatment for non‐small cell lung cancer (NSCLC) carrying the EGFR T790M mutation. With the approval of multiple third‐generation EGFR‐TKIs, questions...

Description complète

Détails bibliographiques

Auteurs principaux:	Yongtong Tang, Jilan Xu, Qingle Chen, Jianping Lu, Li Ren, Taihe Lan, Taihua Liao, Xiaoling Chen, Hui Yi, Jun Zhang, Jie Huang
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2025-02-01
Collection:	Clinical Case Reports
Sujets:	aumolertinib epithelial growth factor receptor osimertinib resistance
Accès en ligne:	https://doi.org/10.1002/ccr3.70219
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!